- Home
- AMGN vs APH Comparison
AMGN vs APH Comparison
Compare AMGN & APH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- APH
- Stock Information
- Founded
- AMGN 1980
- APH 1932
- Country
- AMGN United States
- APH United States
- Employees
- AMGN N/A
- APH N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- APH Electrical Products
- Sector
- AMGN Health Care
- APH Technology
- Exchange
- AMGN Nasdaq
- APH Nasdaq
- Market Cap
- AMGN 150.8B
- APH 167.3B
- IPO Year
- AMGN N/A
- APH 1991
- Fundamental
- Price
- AMGN $334.19
- APH $137.86
- Analyst Decision
- AMGN Hold
- APH Strong Buy
- Analyst Count
- AMGN 14
- APH 11
- Target Price
- AMGN $313.31
- APH $142.73
- AVG Volume (30 Days)
- AMGN 3.1M
- APH 8.5M
- Earning Date
- AMGN 11-04-2025
- APH 10-22-2025
- Dividend Yield
- AMGN 2.85%
- APH 0.73%
- EPS Growth
- AMGN 65.12
- APH 72.40
- EPS
- AMGN 12.93
- APH 3.00
- Revenue
- AMGN $35,971,000,000.00
- APH $20,973,500,000.00
- Revenue This Year
- AMGN $8.82
- APH $51.01
- Revenue Next Year
- AMGN $1.84
- APH $18.43
- P/E Ratio
- AMGN $25.85
- APH $45.96
- Revenue Growth
- AMGN 10.56
- APH 47.36
- 52 Week Low
- AMGN $253.30
- APH $56.45
- 52 Week High
- AMGN $345.84
- APH $144.37
- Technical
- Relative Strength Index (RSI)
- AMGN 61.60
- APH 55.37
- Support Level
- AMGN $330.35
- APH $127.19
- Resistance Level
- AMGN $345.49
- APH $140.69
- Average True Range (ATR)
- AMGN 9.24
- APH 5.01
- MACD
- AMGN 0.26
- APH -1.09
- Stochastic Oscillator
- AMGN 68.68
- APH 61.58
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. It holds the second-largest connector market share globally and sells into the automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks end markets. Amphenol is diversified geographically, with operations in 40 countries.